These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 36115960)

  • 1. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis.
    Gao TT; Shan JH; Yang YX; Zhang ZW; Liu SL; Xi M; Liu MZ; Zhao L
    BMC Cancer; 2022 Sep; 22(1):992. PubMed ID: 36115960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores.
    Chen W; Cao K; Zhang L; Zhao X; Chen B; Li W; Shang R; Sun L; Jiang Z; Wang J; Xue W
    Front Immunol; 2024; 15():1414753. PubMed ID: 39050848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitors
    Liu S; Dou L; Li S
    Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.
    Li ZC; Sun YT; Lai MY; Zhou YX; Qiu MZ
    Int Immunopharmacol; 2022 Aug; 109():108790. PubMed ID: 35504202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis.
    Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J
    BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis.
    Gao Z; Huang S; Wang S; Tang D; Xu W; Zeng R; Qiao G
    Lancet Reg Health West Pac; 2023 Sep; 38():100841. PubMed ID: 37457900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of First-line Therapies for Advanced Unresectable Oesophageal Squamous Cell Cancer: a Systematic Review and Network Meta-analysis.
    Nian Z; Zhao Q; He Y; Xie R; Liu W; Chen T; Huang S; Dong L; Huang R; Yang L
    Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):30-38. PubMed ID: 37827946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
    Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
    Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
    Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
    JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y; Wang W; Wang F
    Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial.
    Zhao W; Ke S; Cai X; Zuo Z; Shi W; Qiu H; Cai G; Gong Y; Wu Y; Ruan S; Chen Y
    Radiother Oncol; 2023 Jul; 184():109679. PubMed ID: 37105302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
    Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
    Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1 inhibitors in advanced esophageal squamous cell carcinoma: a survival analysis of reconstructed patient-level data.
    Yan C; Cao W; Li J; Zhang L; Diao R
    Front Pharmacol; 2024; 15():1408458. PubMed ID: 39092218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis.
    Lin S; Liu T; Chen J; Li G; Dang J
    PLoS One; 2021; 16(6):e0252751. PubMed ID: 34086780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
    Zhu X; Shanzhou Q; Li D; Pang X; Ma D
    BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
    Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis.
    Gong S; Li Q; Yu X; Yang S
    Front Immunol; 2024; 15():1362537. PubMed ID: 38694505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint.
    Zhang Z; Xie C; Gao T; Yang Y; Yang Y; Zhao L
    BMC Cancer; 2023 Feb; 23(1):145. PubMed ID: 36765311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis.
    Lombardi P; Filetti M; Falcone R; Di Bidino R; Iacovelli R; Ciccarese C; Bria E; Tortora G; Scambia G; Daniele G
    Cancer Treat Rev; 2022 May; 106():102377. PubMed ID: 35313232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.